Arcadia Biosciences Inc (RKDA)
Official siteCONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ
Market Cap: $1.32M
Last updated: Nov 17, 2026 at 11:04 AM ET
Arcadia Biosciences Inc (RKDA) Earnings: Report Dates and Results
Arcadia Biosciences (RKDA) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Arcadia Biosciences reported EPS of $0.29. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
RKDA has an expected report date of Mar 24, 2027.
RKDA Earnings Call
The latest RKDA earnings call transcript on file is labeled 2025Q1.
Read the 2025Q1 transcriptEarnings History
Of the 37 quarters below that had an estimate, RKDA beat 19 and missed 18. Revenue for the quarter ended Sep 30, 2026 was $1.62M, up 24.6% from $1.30M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.29 | N/A | N/A | N/A | N/A | -53.2% | N/A | N/A | Nov 12, 2026 | $1.62M |
| Jun 30, 2026 | -$0.38 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2026 | $1.44M |
| Mar 31, 2026 | -$2.11 | -$0.80 | -$0.80 - -$0.80 | N/A | N/A | -210.8% | 1 | 0 up, 0 down | May 14, 2026 | $1.10M |
| Dec 31, 2025 | -$0.98 | -$0.09 | N/A | -984.33% | Miss | N/A | N/A | N/A | Mar 26, 2026 | $901000 |
| Sep 30, 2025 | $0.62 | -$0.54 | -$0.54 - -$0.54 | +214.81% | Beat | N/A | 1 | 0 up, 1 down | Nov 7, 2025 | $1.30M |
| Jun 30, 2025 | -$3.26 | -$0.79 | N/A | -312.66% | Miss | -517.9% | N/A | 0 up, 0 down | Aug 14, 2025 | $1.46M |
| Mar 31, 2025 | $1.90 | -$0.98 | N/A | +293.88% | Beat | N/A | N/A | 0 up, 0 down | May 8, 2025 | $1.20M |
| Dec 31, 2024 | -$2.99 | -$0.89 | N/A | -235.96% | Miss | N/A | N/A | 0 up, 0 down | Mar 20, 2025 | $1.22M |
| Sep 30, 2024 | -$0.87 | -$0.77 | -$0.85 - -$0.77 | -12.99% | Miss | N/A | 2 | 0 up, 0 down | Nov 12, 2024 | $1.54M |
| Jun 30, 2024 | $0.78 | $1.55 | $1.27 - $1.83 | -49.68% | Miss | +27.9% | 2 | 0 up, 0 down | Aug 13, 2024 | $1.31M |
| Mar 31, 2024 | -$1.78 | -$2.21 | -$2.52 - -$1.91 | +19.46% | Beat | N/A | 2 | 1 up, 0 down | May 9, 2024 | $987000 |
| Dec 31, 2023 | -$2.52 | -$2.58 | -$2.68 - -$2.49 | +2.33% | Beat | N/A | 2 | 0 up, 0 down | Mar 28, 2024 | $627000 |
| Sep 30, 2023 | -$1.89 | -$2.93 | N/A | +35.49% | Beat | N/A | 1 | 0 up, 0 down | Nov 9, 2023 | $1.30M |
| Jun 30, 2023 | $0.61 | -$4.92 | N/A | +112.40% | Beat | N/A | 2 | 0 up, 0 down | Aug 10, 2023 | $1.30M |
| Mar 31, 2023 | -$10.86 | -$6.60 | N/A | -64.55% | Miss | N/A | 1 | 1 up, 0 down | May 11, 2023 | $1.23M |
| Dec 31, 2022 | -$6.29 | -$6.80 | -$6.80 - -$6.80 | +7.50% | Beat | N/A | 1 | 0 up, 0 down | Mar 30, 2023 | N/A |
| Sep 30, 2022 | -$7.70 | -$7.60 | -$9.20 - -$7.60 | -1.32% | Miss | N/A | 2 | 0 up, 0 down | Nov 10, 2022 | $1.57M |
| Jun 30, 2022 | -$8.28 | -$12.40 | N/A | +33.23% | Beat | N/A | N/A | 0 up, 0 down | Aug 11, 2022 | $3.86M |
| Mar 31, 2022 | -$8.74 | -$12.40 | -$14.80 - -$12.40 | +29.52% | Beat | N/A | 2 | 0 up, 0 down | May 12, 2022 | $3.22M |
| Dec 31, 2021 | -$11.20 | -$12.00 | -$12.80 - -$11.20 | +6.67% | Beat | -131.8% | 2 | 0 up, 0 down | Mar 30, 2022 | $2.17M |
| Sep 30, 2021 | -$12.35 | -$9.60 | -$14.40 - -$9.20 | -28.65% | Miss | N/A | 3 | 0 up, 1 down | Nov 15, 2021 | $2.38M |
| Jun 30, 2021 | -$8.76 | -$9.20 | -$14.40 - -$9.20 | +4.78% | Beat | N/A | 3 | N/A | Aug 16, 2021 | $1.41M |
| Mar 31, 2021 | -$11.86 | -$12.20 | -$15.60 - -$8.80 | +2.79% | Beat | N/A | 2 | N/A | May 17, 2021 | $828000 |
| Dec 31, 2020 | $35.20 | -$16.40 | -$17.60 - -$15.20 | +314.63% | Beat | N/A | 2 | N/A | Mar 30, 2021 | $7.13M |
| Sep 30, 2020 | -$25.52 | -$21.60 | -$22.40 - -$20.80 | -18.15% | Miss | N/A | 3 | N/A | Nov 12, 2020 | $314000 |
| Jun 30, 2020 | -$28.56 | -$24.20 | -$28.00 - -$20.40 | -18.02% | Miss | N/A | 3 | N/A | Aug 13, 2020 | $281000 |
| Mar 31, 2020 | -$25.80 | -$19.20 | -$24.40 - -$19.20 | -34.38% | Miss | N/A | 2 | N/A | May 13, 2020 | $309000 |
| Dec 31, 2019 | -$20.00 | -$23.00 | -$24.40 - -$21.60 | +13.04% | Beat | N/A | 2 | N/A | Mar 25, 2020 | $416000 |
| Sep 30, 2019 | -$36.93 | -$31.20 | -$32.80 - -$28.40 | -18.37% | Miss | N/A | 3 | N/A | Nov 6, 2019 | $392000 |
| Jun 30, 2019 | -$41.50 | -$37.60 | N/A | -10.37% | Miss | N/A | 2 | N/A | Aug 14, 2019 | $203000 |
| Mar 31, 2019 | -$34.48 | -$40.40 | -$40.40 - -$24.40 | +14.65% | Beat | N/A | 2 | N/A | May 8, 2019 | $158000 |
| Dec 31, 2018 | -$5.60 | -$30.40 | -$30.40 - -$30.40 | +81.58% | Beat | N/A | 1 | N/A | Mar 27, 2019 | $444000 |
| Sep 30, 2018 | -$33.26 | -$45.20 | -$45.20 - -$45.20 | +26.42% | Beat | N/A | 1 | N/A | Nov 7, 2018 | $370000 |
| Jun 30, 2018 | -$80.80 | -$51.60 | N/A | -56.59% | Miss | N/A | N/A | N/A | Aug 8, 2018 | $436000 |
| Mar 31, 2018 | -$194.40 | -$56.00 | N/A | -247.14% | Miss | N/A | N/A | N/A | May 9, 2018 | $214000 |
| Dec 31, 2017 | -$1.39 | -$2.00 | N/A | +30.50% | Beat | N/A | N/A | N/A | Mar 20, 2018 | $1.43M |
| Sep 30, 2017 | -$67.92 | -$64.00 | N/A | -6.13% | Miss | N/A | N/A | N/A | Nov 9, 2017 | $589000 |
| Jun 30, 2017 | -$72.00 | -$88.00 | N/A | +18.18% | Beat | N/A | N/A | N/A | Aug 10, 2017 | $991000 |
| Mar 31, 2017 | -$80.00 | -$56.00 | N/A | -42.86% | Miss | N/A | N/A | N/A | May 10, 2017 | $1.02M |
| Dec 31, 2016 | -$104.00 | -$80.00 | N/A | -30.00% | Miss | N/A | N/A | N/A | Mar 8, 2017 | $540000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.72, after -$4.86 the year before. It was -$352.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.72 | N/A |
| Dec 31, 2024 | -$4.86 | N/A |
| Dec 31, 2023 | -$14.66 | N/A |
| Dec 31, 2022 | -$31.01 | N/A |
| Dec 31, 2021 | -$44.17 | N/A |
| Dec 31, 2020 | -$44.68 | N/A |
| Dec 31, 2019 | -$132.91 | N/A |
| Dec 31, 2018 | -$314.06 | N/A |
| Dec 31, 2017 | -$221.31 | N/A |
| Dec 31, 2016 | -$352.00 | N/A |
Earnings Calls
The 4 most recent earnings calls are listed below; the latest, 2025Q1 for the period ended Mar 31, 2025, runs about 3,200 words across 4 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q1 | Mar 31, 2025 | 3,202 | 4 | |
| 2024Q4 | Dec 31, 2024 | 2,534 | 4 | |
| 2024Q3 | Sep 30, 2024 | 1,897 | 4 | |
| 2024Q2 | Jun 30, 2024 | 3,397 | 5 |
2025Q1 Earnings Call
Opening remarks
Mark Kawakami CFO Thank you. Joining me on the call today is T.J. Schaefer, Arcadia's President and Chief Executive Officer. This call is being webcast, and you can refer to the company's press release at ArcadiaBio.com. Before we start, I would like to remind you that Arcadia Biosciences, Inc. will be making forward-looking statements on this call based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied today. You can review the company's safe harbor language in our most recently filed 10-K. With that, I will now turn the call over to T.J. Schaefer.
T.J. Schaefer President & CEO Thanks, Mark, and thank you to everyone on the call for joining us today to discuss our 2025 first quarter financial results. It has only been seven weeks since we delivered our 2024 year-end update, but the momentum from the second half of 2024 has carried into 2025, and I am very pleased with our first quarter results. Zola coconut water continues to thrive and outperform our own internal expectations. In Q1 2025, our revenue grew 90% year-over-year, primarily driven by new distribution gains, which increased 70% compared to the same period last year. We continue to implement tight cost controls, resulting in strong gross margins and a 16% year-over-year reduction in operating expenses, inclusive of nearly half a million dollars in transaction-related fees during the quarter. In addition to our strong brand performance, we also made significant progress during the quarter monetizing our intellectual property, a goal we have discussed for several years. Finally, the pending business combination with Roosevelt Resources continues to move forward, and we believe it is on track to be completed towards the end of the summer. Today, I would like to discuss each of these topics in more detail, starting with the performance of Zola. As I just mentioned, our revenue from Zola increased 90% compared to the same quarter last year, primarily driven by a 70% increase in new distribution. Growing Zola's presence in the marketplace has been a focus of Arcadia Biosciences, Inc., and we believe it represents our best opportunity to significantly increase our share of coconut water industry sales, given our relatively low penetration rate. Our sell-through or scan data sales increased 76% during the 13 weeks ended March 29, 2025, based on Nielsen data. This rate of sales growth is more than three times faster than the coconut water category, which grew 24% during the same time period. Coconut water continues to outpace the growth of many other beverage categories, driven by the shift in consumer preferences toward healthy, better-for-you beverages.
Frequently Asked Questions About RKDA
When is Arcadia Biosciences's next earnings date?
Arcadia Biosciences's next earnings report is expected for Mar 24, 2027.
How often does RKDA beat earnings estimates?
Arcadia Biosciences beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -133.43%.
RKDA pages: Overview, Earnings, Financials, Valuation, Competitors